These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 30070580

  • 1. Lixisenatide requires a functional gut-vagus nerve-brain axis to trigger insulin secretion in controls and type 2 diabetic mice.
    Charpentier J, Waget A, Klopp P, Magnan C, Cruciani-Guglielmacci C, Lee SJ, Burcelin R, Grasset E.
    Am J Physiol Gastrointest Liver Physiol; 2018 Nov 01; 315(5):G671-G684. PubMed ID: 30070580
    [Abstract] [Full Text] [Related]

  • 2. Effects of glucagon-like peptide-1 receptor agonists on secretions of insulin and glucagon and gastric emptying in Japanese individuals with type 2 diabetes: A prospective, observational study.
    Kuwata H, Yabe D, Murotani K, Fujiwara Y, Haraguchi T, Kubota S, Kubota-Okamoto S, Usui R, Ishitobi M, Yamazaki Y, Hamamoto Y, Kurose T, Seino Y, Yamada Y, Seino Y.
    J Diabetes Investig; 2021 Dec 01; 12(12):2162-2171. PubMed ID: 34022121
    [Abstract] [Full Text] [Related]

  • 3. The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
    Christensen M, Miossec P, Larsen BD, Werner U, Knop FK.
    Expert Opin Drug Discov; 2014 Oct 01; 9(10):1223-51. PubMed ID: 25119443
    [Abstract] [Full Text] [Related]

  • 4. Effects of Lixisenatide Versus Liraglutide (Short- and Long-Acting GLP-1 Receptor Agonists) on Esophageal and Gastric Function in Patients With Type 2 Diabetes.
    Quast DR, Schenker N, Menge BA, Nauck MA, Kapitza C, Meier JJ.
    Diabetes Care; 2020 Sep 01; 43(9):2137-2145. PubMed ID: 32647054
    [Abstract] [Full Text] [Related]

  • 5. Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.
    Horowitz M, Rayner CK, Jones KL.
    Adv Ther; 2013 Feb 01; 30(2):81-101. PubMed ID: 23423907
    [Abstract] [Full Text] [Related]

  • 6. Effects of Sustained Treatment With Lixisenatide on Gastric Emptying and Postprandial Glucose Metabolism in Type 2 Diabetes: A Randomized Controlled Trial.
    Rayner CK, Watson LE, Phillips LK, Lange K, Bound MJ, Grivell J, Wu T, Jones KL, Horowitz M, Ferrannini E, Tricò D, Frascerra S, Mari A, Natali A.
    Diabetes Care; 2020 Aug 01; 43(8):1813-1821. PubMed ID: 32471908
    [Abstract] [Full Text] [Related]

  • 7. GLP-1 receptor agonist liraglutide exerts central action to induce β-cell proliferation through medulla to vagal pathway in mice.
    Kumari P, Nakata M, Zhang BY, Otgon-Uul Z, Yada T.
    Biochem Biophys Res Commun; 2018 May 15; 499(3):618-625. PubMed ID: 29601817
    [Abstract] [Full Text] [Related]

  • 8. The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial.
    Juel CTB, Lund A, Andersen MM, Hansen CP, Storkholm JH, Rehfeld JF, van Hall G, Hartmann B, Wewer Albrechtsen NJ, Holst JJ, Vilsbøll T, Knop FK.
    Diabetologia; 2020 Jul 15; 63(7):1285-1298. PubMed ID: 32394228
    [Abstract] [Full Text] [Related]

  • 9. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying--preclinical evidence.
    Werner U.
    J Diabetes Complications; 2014 Jul 15; 28(1):110-4. PubMed ID: 23992745
    [Abstract] [Full Text] [Related]

  • 10. Treatment potential of the GLP-1 receptor agonists in type 2 diabetes mellitus: a review.
    Østergaard L, Frandsen CS, Madsbad S.
    Expert Rev Clin Pharmacol; 2016 Jul 15; 9(2):241-65. PubMed ID: 26573176
    [Abstract] [Full Text] [Related]

  • 11. Pharmacological profile of lixisenatide: A new GLP-1 receptor agonist for the treatment of type 2 diabetes.
    Werner U, Haschke G, Herling AW, Kramer W.
    Regul Pept; 2010 Sep 24; 164(2-3):58-64. PubMed ID: 20570597
    [Abstract] [Full Text] [Related]

  • 12. Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects.
    Becker RH, Stechl J, Steinstraesser A, Golor G, Pellissier F.
    Diabetes Metab Res Rev; 2015 Sep 24; 31(6):610-8. PubMed ID: 25773712
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 and islet lipolysis.
    Sörhede Winzell M, Ahrén B.
    Horm Metab Res; 2004 Sep 24; 36(11-12):795-803. PubMed ID: 15655711
    [Abstract] [Full Text] [Related]

  • 14. Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials.
    Ahrén B, Gautier JF, Berria R, Stager W, Aronson R, Bailey CJ.
    Diabetes Obes Metab; 2014 Sep 24; 16(9):861-8. PubMed ID: 24641271
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lixisenatide: A New Daily GLP-1 Agonist for Type 2 Diabetes Management.
    McCarty D, Coleman M, Boland CL.
    Ann Pharmacother; 2017 May 24; 51(5):401-409. PubMed ID: 28133970
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ.
    Expert Opin Emerg Drugs; 2004 May 24; 9(1):155-66. PubMed ID: 15155141
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Sgemaglutide in type 2 diabetes - is it the best glucagon-like peptide 1 receptor agonist (GLP-1R agonist)?
    Doggrell SA.
    Expert Opin Drug Metab Toxicol; 2018 Mar 24; 14(3):371-377. PubMed ID: 29439603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.